TopOptionAlert
Oct 24, 12:11 PM
$ABBV NOV20 295C · in play
Zone:
$284 to
$288
Invalidation: close under
$280
Objectives:
$291.50, then
$300
The math: up 2.1% to the first objective and 5.0% to the second, against 2.0% risk on the invalidation, better than 2 to 1 to the second.
Think of this as a swing into earnings week for a stock that is already knocking on its own front door. AbbVie closed Friday near
$286, just under its 52 week high near
$291.40, after the FDA cleared an at home start for Skyrizi and fresh trial wins kept the story moving. If buyers push it through that high into the October 30 report, the next clean stopping point is the round
$300 level, and the plan stays simple: strength above the zone keeps the idea alive, a close under
$280 says the timing was wrong.
P.S. Watch the October 30 report before the market opens: it is the first real test of whether Skyrizi and Rinvoq can keep carrying growth while Humira fades.
0 replies
